Vanguard Group’s Bluejay Diagnostics BJDX Stock Holding History

Vanguard Group’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Hold	0	–	-$4.18K	–	4545
2023 Q2	–	Hold	0	–	–	–	4546
2023 Q1	–	Hold	0	–	–	–	4547
2022 Q4	–	Hold	0	–	–	–	4523
2022 Q3	–	Hold	0	–	–	–	4598
2022 Q1	–	Sell	-1	Closed	-$82K	–	4631
2021 Q4	$82K	Buy	+1	New	+$98.3K	﹤0.01%	4617

Other funds holding BJDX

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's BJDX Position: Q3 2023 in Review

Vanguard Group held its Bluejay Diagnostics (BJDX) position steady in Q3 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4545.

Vanguard Group first reported a position in BJDX in Q4 2021 and has held it in 1 quarter since. The position peaked at $82K in Q4 2021. 2 funds tracked by Wall St. Rank hold BJDX as of Q3 2023.

Vanguard Group held 0 shares of Bluejay Diagnostics worth $0 as of Q3 2023.
Vanguard Group left its Bluejay Diagnostics share count unchanged in Q3 2023.
Bluejay Diagnostics made up ﹤0.01% of Vanguard Group's portfolio in Q3 2023, its #4545 holding.
Vanguard Group first reported a position in Bluejay Diagnostics in Q4 2021 and has held it in 1 quarter since.
Vanguard Group's Bluejay Diagnostics position peaked at $82K in Q4 2021.
2 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.